Brief: Moleculin Announces Positive Interim Data In Annamycin Clinical Trials
13/11/2023 14:52
Nov 13 (Reuters) - Moleculin Biotech Inc MBRX.O :
* MOLECULIN ANNOUNCES POSITIVE INTERIM DATA IN ANNAMYCIN
CLINICAL
TRIALS: MB-106 AML TRIAL COMPLETE RESPONSE (CR) RATE OF 38% AND
MB-107 STS LUNG METS TRIAL MEDIAN PHASE 1B EXTENDED OVERALL
SURVIVAL OF 11 MONTHS
Source text for Eikon: ID:nPn5Z19dya
Further company coverage: MBRX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Moleculin Biotech
See all newsMoleculin Biotech Inc reports results for the quarter ended September 30 - Earnings Summary
Brief: Moleculin Secures Australian Patent For Annamycin Formulation Technology
Moleculin Biotech Inc expected to post a loss of $8.87 a share - Earnings Preview
Brief: Moleculin Biotech Completes Dosing In Part A Of Miracle Trial Data Readout On Track For Q1 2027
NASDAQ RESUMED AT 09:00 AM